VERAXA Biotech AG (NASDAQ: VRXA) provided a corporate and pipeline update on Wednesday, detailing progress during the first half of 2026, including continued advancement of its proprietary BiTAC(R) platform and growing interest from potential pharmaceutical partners. The company's pipeline now includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate (ADC) programs, and two non-BiTAC assets available for partnering.
VERAXA said it plans to prioritize investment in its BiTAC portfolio while seeking to monetize selected non-BiTAC programs to help finance future development. The goal is to advance lead BiTAC-TCE candidate VXA-102 to IND/CTA readiness by early 2028. Company executives cited strong industry interest in T-cell engager and ADC technologies, noting that recent partnering discussions at the BIO International Convention and other scientific meetings reinforced confidence in the company's differentiated BiTAC platform and its potential to secure strategic collaborations.
The company said it continues to refine both its pipeline and partnering strategy as it advances its next generation of cancer therapies. For more details, the full press release is available at https://ibn.fm/xTF5q.
VERAXA Biotech AG is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
BiTAC(R) is a registered trademark of VERAXA Biotech GmbH. For the latest news and updates relating to VRXA, visit the company's newsroom at http://ibn.fm/VRXA.
This update underscores VERAXA's commitment to advancing its proprietary BiTAC platform amid a favorable partnering environment for T-cell engagers and ADCs. The company's strategy to prioritize BiTAC programs while monetizing non-core assets could provide a pathway to finance development without excessive dilution, positioning it to potentially become a key player in the next wave of cancer immunotherapy.
